YOLT 201
Alternative Names: YOLT-201Latest Information Update: 16 Jul 2024
At a glance
- Originator YolTech Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Prealbumin expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Transthyretin-related hereditary amyloidosis
Most Recent Events
- 11 Jul 2024 Phase-I/II clinical trials in Transthyretin-related hereditary amyloidosis in China (IV) (CTR20241309)
- 04 Mar 2024 Center for Drug Evaluation of the National Medical Products Administration (NMPA) approves IND application for YOLT 201 in Transthyretin-related hereditary amyloidosis
- 04 Mar 2024 Efficacy and adverse events data from phase I trial in Transthyretin-related hereditary amyloidosis released by YolTech Therapeutics